The therapeutic community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s showing significant efficacy in clinical trials for addressing obesity. Unlike some current weight loss approaches, retatrutide appears to deliver a significant substantial reduction in body size and improve metabolic function